Ocular Therapeutix
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ocular Therapeutix generated cash of -$70,234,000, which is less than the previous year. Cash used in financing activities reached the amount of $169,828,000 last year. Net change in cash is therefore $93,507,000.
Cash Flow
| 2014 | -20.49M | -38.58M | 78.97M |
|---|---|---|---|
| 2015 | -33.74M | -38.56M | 65.70M |
| 2016 | -34.00M | 35.56M | 585K |
| 2017 | -50.47M | 27.06M | 32.00M |
| 2018 | -49.22M | -1.88M | 68.64M |
| 2019 | -77.57M | -2.23M | 75.34M |
| 2020 | -53.55M | -841K | 228.01M |
| 2021 | -65.55M | -1.19M | 2.85M |
| 2022 | -59.60M | -3.71M | 1.45M |
| 2023 | -70.23M | -6.08M | 169.82M |
OCUL Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 104.06M | 165.92M | 229.82M | 56.20M | 60.67M | 43.15M | 32.93M | 30.78M | 37.39M | 17.50M |
Operating activities | ||||||||||
Net income | -80.73M | -71.03M | -6.55M | -155.63M | -86.37M | -59.97M | -63.38M | -44.70M | -39.74M | -28.64M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.98M | 2.10M | 2.42M | 2.77M | 2.53M | 2.28M | 1.62M | 881K | 754K | 547K |
Stock-based compensation expense | 17.82M | 16.96M | 14.97M | 7.53M | 8.75M | 0 | 7.32M | 5.95M | 4.64M | 2.64M |
| Deferred income tax benefit | 17.82M | 16.96M | 14.97M | 7.53M | 8.75M | 0 | 7.32M | 5.95M | 4.64M | 2.64M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -4.85M | -190K | -8.88M | -9.70M | -2.34M | 25K | 24K | -57K | 136K | -60K |
Inventories | -331K | -724K | -49K | -247K | -737K | -95K | -9K | 21K | -1K | -133K |
Accounts payable | 583K | -621K | 1.79M | -452K | 124K | -796K | 932K | -159K | 348K | 507K |
Cash generated by operating activities | -70.23M | -59.60M | -65.55M | -53.55M | -77.57M | -49.22M | -50.47M | -34.00M | -33.74M | -20.49M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -3M | -41.69M | -91.68M | -37.32M |
Investments In Property Plant And Equipment | -6.08M | -3.71M | -1.19M | -841K | -2.23M | -1.88M | -8.25M | -1.91M | -1.77M | -1.26M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 5K | 2K | 7K | 0 |
Cash generated by investing activities | -6.08M | -3.71M | -1.19M | -841K | -2.23M | -1.88M | 27.06M | 35.56M | -38.56M | -38.58M |
Financing activities | ||||||||||
Common Stock Issued | 117.26M | 1.45M | 3.29M | 228.01M | 37.53M | 61.57M | 29.23M | 0 | 65.61M | 69.51M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 297K | 0 | 0 | 0 | 64K |
Repayments of term debt | 56.34M | 0 | -445K | -3.20M | 37.27M | -5.65M | 2.4M | 0 | 397K | -2.27M |
Cash used in financing activities | 169.82M | 1.45M | 2.85M | 228.01M | 75.34M | 68.64M | 32.00M | 585K | 65.70M | 78.97M |
Net Change In Cash | 93.50M | -61.86M | -63.89M | 173.62M | -4.47M | 17.52M | 8.60M | 2.15M | -6.60M | 19.88M |
Cash at end of period | 197.57M | 104.06M | 165.92M | 229.82M | 56.20M | 60.67M | 41.53M | 32.93M | 30.78M | 37.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |